Focus: NorthStar Medical Technologies is a Wisconsin-based biotechnology company specializing in medical radioisotopes, with a diversified portfolio spanning neurology, cardiovascular, and oncology applications. The company operates at modest scale with 30 active job openings and generates revenue primarily from generic medications.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Stable — net -4 jobs in 30d
14 added, 18 removed. Backfill posture.
NorthStar offers operational expertise in niche radioisotope manufacturing but carries substantial revenue cliff risk; best suited for manufacturing, QA, or supply-chain professionals seeking stable execution roles rather than pipeline-driven career growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver (100% of company revenue) despite minimal Part D spending; represents critical commercial vulnerability.
Help build intelligence for NorthStar Medical Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NorthStar Medical Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE generic with no disclosed revenue; contributes to portfolio breadth but faces generic competition and opioid market headwinds.
Mature OTC/Rx generic with no disclosed revenue; commodity market with intense price pressure.
Established cardiovascular generic with no disclosed revenue; therapeutic area aligns with company's stated focus but faces generic saturation.
Only NDA product and only asset at peak lifecycle; represents company's core radioisotope expertise and most defensible platform.
Neurologic generic with no disclosed revenue; aligns with stated neurology focus but faces post-exclusivity erosion.
Post-LOE antiemetic generic with no disclosed revenue; subject to known safety profile concerns and generic competition.
Cardiovascular generic with no disclosed revenue; first-line therapy market occupied by generic competition and newer agents.
Psychiatry generic with no disclosed revenue; competes with benzodiazepines and SSRIs in commodity market.
7 discontinued, 3 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo